How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999–2000

Michael A Neaverson
Med J Aust 2009; 190 (4): . || doi: 10.5694/j.1326-5377.2009.tb02363.x
Published online: 16 February 2009

To the Editor: In their recent article, Chen and colleagues argued for an increase in the number of Australians being treated with lipid-lowering drugs.1 It would appear pertinent to question the economic and therapeutic value of such an increase.

  • Michael A Neaverson

  • Nu-Life Cardiac Programmes, Noosaville, QLD.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.